尽管COVID-19大流行,产前诊断危重先天性心脏病的比率持续改善:加拿大多中心研究
该研究纳入加拿大安大略省和阿尔伯塔省所有三级胎儿心脏中心2016年1月1日至2022年3月31日预估分娩的危重先天性心脏病病例,比较COVID-19前与COVID-19期间产前诊断率及妊娠和出生后结局。整体产前诊断率为1238/1774(69.8%),COVID-19暴露组为380/517(73.5%),高于COVID-19前组的858/1257(68.3%)(P=0.03)。调整后产前诊断率持续增加,COVID-19期间呈增加趋势。
要点
- 危重先心病整体产前诊断率为69.8%(1238/1774)。
- COVID-19暴露组产前诊断率73.5%(380/517),高于COVID-19前组68.3%(858/1257)(P=0.03)。
- 两组30天和1年婴儿死亡率无显著差异。
核心结论
- 尽管COVID-19大流行期间临床服务减少,加拿大两个最大省份的危重先心病产前诊断率在大流行期间持续增加。
- 这些发现为资源有限场景下细化胎儿心脏病转诊指征的影响提供了 reassurance。
研究设计与样本
- 来自加拿大安大略省和阿尔伯塔省所有三级胎儿心脏中心的多中心研究。
- 纳入预估分娩日期在2016年1月1日至2022年3月31日之间、需要或预期需要新生儿干预的危重先心病病例。
- 妊娠根据是否在2020年3月1日前或后达到18周妊娠分为COVID-19前组和COVID-19暴露组。
- 采用Cox比例风险模型评估产前诊断率,纳入时变和时不变协变量。
主要发现
- 整体产前诊断率为1238/1774(69.8%),COVID-19前组为858/1257(68.3%),COVID-19暴露组为380/517(73.5%)(P=0.03)。
- COVID-19前组与COVID-19暴露组产科超声中位孕周分别为20.1周(IQR 19.0-22.0) vs 19.8周(IQR 19.1-21.3)(P=0.07),无显著差异。
- COVID-19前组与COVID-19暴露组从产科超声到危重先心病诊断的中位时间分别为1.2周(IQR 0.6-2.2) vs 1.2周(IQR 0.6-2.2)(P=0.59),无显著差异。
- COVID-19前组与COVID-19暴露组22周前产前诊断分别为454/848(53.5%) vs 221/378(58.5%)(P=0.11),无显著差异。
- COVID-19暴露组终止妊娠更常见(COVID-19前组20.9% vs COVID-19期间27.5%;P=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Travel restrictions, reallocation of health resources and physical distancing during the coronavirus disease 2019 (COVID-19) pandemic caused extraordinary strain on healthcare systems. The overall impact of public health measures during COVID-19 on the prenatal diagnosis of congenital heart disease (CHD) has received limited attention. We sought to determine the rate of prenatal diagnosis and the pregnancy and postnatal outcomes of critical CHD prior to and during the COVID-19 pandemic. METHODS: Cases of critical CHD with estimated due date between 1 January 2016 and 31 March 2022 that required or were expected to require neonatal intervention were identified from all tertiary fetal cardiac centers in Ontario and Alberta, Canada. Pregnancies were stratified based on reaching 18 weeks' gestation before (pre-COVID-19) or after 1 March 2020 (during COVID-19), as the latter group would require ultrasound scanning under COVID-19 pandemic restrictions. Outcomes included timing of critical CHD diagnosis (prenatal or postnatal), gestational age at prenatal diagnosis, pregnancy outcome and infant mortality at 30 days and 1 year after birth. The rate of prenatal diagnosis was assessed using Cox proportional hazard modeling with time-varying and time-invariant cofactors. RESULTS: Prenatal diagnosis occurred in 1238/1774 (69.8%) cases of critical CHD overall, of which 858/1257 (68.3%) cases were in the pre-COVID-19 group and 380/517 (73.5%) cases were in the COVID-19 exposure group (P = 0.03). There was no difference between the pre-COVID-19 group and the COVID-19 exposure group in median gestational age at obstetric ultrasound (20.1 (interquartile range (IQR), 19.0-22.0) weeks vs 19.8 (IQR, 19.1-21.3) weeks; P = 0.07), median time from obstetric ultrasound to diagnosis of critical CHD (1.2 (IQR, 0.6-2.2) weeks vs 1.2 (IQR, 0.6-2.2) weeks; P = 0.59) and prenatal diagnosis < 22 weeks' gestation (454/848 (53.5%) vs 221/378 (58.5%); P = 0.11). Termination of pregnancy was more common in the COVID-19 exposure group (pre-COVID-19, 20.9% vs during COVID-19, 27.5%; P = 0.01). Infant mortality at 30 days (pre-COVID-19, 2.5% vs COVID-19, 1.8%; P = 0.44) and at 1 year after birth (pre-COVID-19, 8.9% vs COVID-19, 8.6%; P = 0.86) did not differ between eras. Once adjusted for province, trends in calendar time, week of gestation, distance to closest tertiary fetal cardiac service and genetic diagnosis, the rate of prenatal diagnosis of critical CHD continued to increase, with a trend towards an increased rate during the COVID-19 pandemic compared with the pre-COVID-19 era. CONCLUSIONS: Despite the reduction in clinical services during the COVID-19 pandemic, the rate of prenatal diagnosis of critical CHD continued to increase during the pandemic in two of Canada's largest provinces. These findings provide reassurance regarding the impact of refined fetal cardiology referral indications for resource-limited scenarios. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Eckersley L, Lad M, Rose H, et al. Rate of prenatal diagnosis of critical congenital heart disease continued to improve despite COVID-19 pandemic: multicenter Canadian study. Ultrasound Obstet Gynecol. 2025. PMID: 40975049. doi:10.1002/uog.70028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。